Maze Therapeutics
Maze Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on translating human genetics into precision small molecule medicines for kidney and metabolic diseases. The company utilizes its proprietary Compass platform to advance clinical pipeline candidates targeting APOL1-mediated kidney disease, Pompe disease, and chronic metabolic conditions. Principal revenue is derived from development milestone payments, strategic research collaborations, and licensing partnerships with global pharmaceutical companies. Core end markets encompass nephrology treatment clinics, genetic disease specialists, and biopharmaceutical partners globally. Maze Therapeutics holds an innovative position in the biopharmaceutical sector for genetically validated target discovery and precision small molecule therapeutics. The company is headquartered in South San Francisco, California, operating as a private biotechnology corporation.
2 of the funds FundTelligence covers report a position in Maze Therapeutics.
- Legal name
- MAZE THERAPEUTICS
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Maze Therapeutics
- JPM US Small Cap Growth Fund — JPM · 0.47 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.12 % (full portfolio disclosed, October 2026)